Jennifer Callahan

1.3k total citations
19 papers, 1.0k citations indexed

About

Jennifer Callahan is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Jennifer Callahan has authored 19 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 7 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in Jennifer Callahan's work include Protease and Inhibitor Mechanisms (6 papers), Peptidase Inhibition and Analysis (3 papers) and Blood Coagulation and Thrombosis Mechanisms (3 papers). Jennifer Callahan is often cited by papers focused on Protease and Inhibitor Mechanisms (6 papers), Peptidase Inhibition and Analysis (3 papers) and Blood Coagulation and Thrombosis Mechanisms (3 papers). Jennifer Callahan collaborates with scholars based in United States, United Kingdom and China. Jennifer Callahan's co-authors include Graham C. Parry, Andrew P. Mazar, David E. Shaw, Mingdong Huang, Alice A. Kuo, Douglas B. Cines, Bruce Furie, Qing Huai, Barbara C. Furie and Yongdong Li and has published in prestigious journals such as Science, Journal of Clinical Oncology and Blood.

In The Last Decade

Jennifer Callahan

19 papers receiving 1.0k citations

Peers

Countries citing papers authored by Jennifer Callahan

Since Specialization

Citations

This map shows the geographic impact of Jennifer Callahan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Callahan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Callahan more than expected).

Fields of papers citing papers by Jennifer Callahan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Callahan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Callahan. The network helps show where Jennifer Callahan may publish in the future.

Co-authorship network of co-authors of Jennifer Callahan

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Callahan. A scholar is included among the top collaborators of Jennifer Callahan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Callahan. Jennifer Callahan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis 2018 ·JAMA Oncology ·John Mascarenhas, Ronald Hoffman, Moshe Talpaz, Aaron T. Gerds, Brady L. Stein, Vikas Gupta, Anita Szőke, Mark W. Drummond, Alexander Pristupa, Tanya Granston, Robert Daly, Suliman Al‐Fayoumi, Jennifer Callahan, Jack W. Singer, Jason Gotlib, Catriona Jamieson, Claire Harrison, Ruben A. Mesa, Srđan Verstovšek	255
2	Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl 2016 ·Blood ·John Mascarenhas, Ronald Hoffman, Moshe Talpaz, Aaron T. Gerds, Brady L. Stein, Vikas Gupta, Anita Szőke, Mark W. Drummond, Alexander Pristupa, Tanya Granston, Robert Daly, James P. Dean, Suliman Al‐Fayoumi, Jennifer Callahan, Jack W. Singer, Jason Gotlib, Catriona Jamieson, Claire Harrison, Ruben A. Mesa, Srđan Verstovšek	30
3	Lipopolysaccharide induction of autophagy is associated with enhanced bactericidal activity in Dictyostelium discoideum 2012 ·Biochemical and Biophysical Research Communications ·(unknown), (unknown), (unknown), Jennifer Callahan, (unknown)	10
4	Lipopolysaccharide enhances bactericidal activity in Dictyostelium discoideum cells 2011 ·Developmental & Comparative Immunology ·(unknown), Jennifer Callahan, (unknown), (unknown), (unknown), (unknown), (unknown)	11
5	A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer 2011 ·Urologic Oncology Seminars and Original Investigations ·Jianqing Lin, Marianna Zahurak, Tomasz M. Beer, Charles J. Ryan, George Wilding, Paul Mathew, Michael J. Morris, Jennifer Callahan, (unknown), Steven D. Reich, Michael A. Carducci, Emmanuel S. Antonarakis	53
6	A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial 2009 ·Journal of Clinical Oncology ·Jianqing Lin, Tomasz M. Beer, Charles J. Ryan, Paul Mathew, George Wilding, Michael J. Morris, Jennifer Callahan, Gary Gordon, Stephen G. Reich, Michael A. Carducci	6
7	Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes 2008 ·Nature Structural & Molecular Biology ·Qing Huai, Aiwu Zhou, Lin Lin, Andrew P. Mazar, Graham C. Parry, Jennifer Callahan, David E. Shaw, Bruce Furie, Barbara C. Furie, Mingdong Huang	96
8	An Anti-urokinase Plasminogen Activator Receptor (uPAR) Antibody: Crystal Structure and Binding Epitope 2006 ·Journal of Molecular Biology ·Yongdong Li, Graham C. Parry, Liqing Chen, Jennifer Callahan, David E. Shaw, Edward J. Meehan, Andrew P. Mazar, Mingdong Huang	18
9	Structural Basis of Interaction between Urokinase-type Plasminogen Activator and its Receptor 2006 ·Journal of Molecular Biology ·Cyril Bařinka, Graham C. Parry, Jennifer Callahan, David E. Shaw, Alice A. Kuo, Khalil Bdeir, Douglas B. Cines, Andrew P. Mazar, J. Łubkowski	94
10	Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies. 2006 ·Blood ·James R. Berenson, Ralph V. Boccia, Asad Bashey, Alexandra M. Levine, Omer N. Koç, Jennifer Callahan, Andrew P. Mazar, Steven D. Reich	4
11	Structure of Human Urokinase Plasminogen Activator in Complex with Its Receptor 2006 ·Science ·Qing Huai, Andrew P. Mazar, Alice A. Kuo, Graham C. Parry, David E. Shaw, Jennifer Callahan, Yongdong Li, Cai Yuan, Chuanbing Bian, Liqing Chen, Bruce Furie, Barbara C. Furie, Douglas B. Cines, Mingdong Huang	244
12	Targeting of Urokinase Plasminogen Activator Receptor in Human Pancreatic Carcinoma Cells Inhibits c-Met– and Insulin-like Growth Factor-I Receptor–Mediated Migration and Invasion and Orthotopic Tumor Growth in Mice 2005 ·Cancer Research ·Todd W. Bauer, Wenbiao Liu, Fan Fan, E. Ramsay Camp, Anthony Yang, Ray Somcio, Corazon D. Bucana, Jennifer Callahan, Graham C. Parry, Douglas B. Evans, Douglas D. Boyd, Andrew P. Mazar, Lee M. Ellis	120
13	In vitro and in vivo characterization of a monoclonal antibody, ATN-658, targeting the uPA system 2005 ·Cancer Research ·Jennifer Callahan, (unknown), Todd W. Bauer, Lee M. Ellis, Andrew P. Mazar, Graham C. Parry	2
14	Insulinlike Growth Factor-I???Mediated Migration and Invasion of Human Colon Carcinoma Cells Requires Activation of c-Met and Urokinase Plasminogen Activator Receptor 2005 ·Annals of Surgery ·Todd W. Bauer, Fan Fan, Wenbiao Liu, (unknown), Nila U. Parikh, Graham C. Parry, Jennifer Callahan, Andrew P. Mazar, Gary E. Gallick, Lee M. Ellis	54
15	Optimization of Crystals of an Inhibitory Antibody of Urokinase Plasminogen Activator Receptor (uPAR) with Hydrogen Peroxide and Low Protein Concentration 2005 ·Protein and Peptide Letters ·Yongdong Li, Xiaoli Shi, Graham C. Parry, Liqing Chen, Jennifer Callahan, Andrew P. Mazar, Mingdong Huang	1
16	Intracellular forms of human NOTCH1 interact at distinctly different levels with RBP-Jkappa in human B and T cells 2000 ·Leukemia ·Jennifer Callahan, Jon C. Aster, Jeffrey Sklar, Elliott Kieff, (unknown)	8
17	Intracellular Forms of Human NOTCH1 Functionally Activate Essential Epstein-Barr Virus Major Latent Promoters in the Burkitt's Lymphoma BJAB Cell Line but Repress These Promoters in Jurkat Cells 2000 ·Journal of Virology ·Murray A. Cotter, Jennifer Callahan, Jon C. Aster, Erle S. Robertson	9
18	Distinct Patterns of Viral Antigen Expression in Epstein–Barr Virus and Kaposi's Sarcoma-Associated Herpesvirus Coinfected Body-Cavity-Based Lymphoma Cell Lines: Potential Switches in Latent Gene Expression Due to Coinfection 1999 ·Virology ·Jennifer Callahan, (unknown), Murray A. Cotter, (unknown)	28
19	Studies of Cultured Human T Lymphocytes II. Initiation of Paired T- and B-Cell Lines from Healthy Donors 1983 ·Experimental Biology and Medicine ·John L. Pauly, (unknown), (unknown), (unknown), (unknown), Jennifer Callahan, Jun Minowada	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact